Amgen

Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors

Retrieved on: 
Tuesday, December 12, 2023

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the appointment of R. Keith Woods as an independent, non-executive director to its Board of Directors.

Key Points: 
  • Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the appointment of R. Keith Woods as an independent, non-executive director to its Board of Directors.
  • Mr. Woods is a seasoned executive with more than 30 years of experience spanning commercialization, global operations, business strategy and supply chain.
  • “I’m thrilled to welcome Keith to our Board of Directors, who brings deep industry expertise and invaluable experience to the Rocket Board as we build upon our commercial and operational infrastructure to support our anticipated first product launches for severe Leukocyte Adhesion Deficiency (LAD-I) and Fanconi Anemia (FA),” said Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharma.
  • Earlier in his career, Mr. Woods held commercial and sales positions of increasing responsibility at Roche, Amgen and Eisai.

Agomab Appoints Angelika Jahreis as Member of the Board of Directors and Andrea Sáez as Chief Development Officer

Retrieved on: 
Wednesday, November 29, 2023

Agomab Therapeutics NV (‘Agomab’), a company developing differentiated programs with disease-modifying potential in fibrotic diseases, announced today the appointment of Angelika Jahreis, MD, PhD, as an independent non-executive director to Agomab’s Board of Directors, while Andrea Sáez, PhD, will join Agomab’s executive leadership team as Chief Development Officer.

Key Points: 
  • Agomab Therapeutics NV (‘Agomab’), a company developing differentiated programs with disease-modifying potential in fibrotic diseases, announced today the appointment of Angelika Jahreis, MD, PhD, as an independent non-executive director to Agomab’s Board of Directors, while Andrea Sáez, PhD, will join Agomab’s executive leadership team as Chief Development Officer.
  • As part of the next growth phase of the company, Paolo Michieli, PhD, (Founder and formerly Chief Scientific Officer) and Torsten Dreier, PhD, (previously Chief Development Officer) will continue at Agomab as senior advisors and members of the Scientific Advisory Board (SAB).
  • “Angelika’s extensive experience and deep knowledge as a senior drug developer will be of great value to the Board and our company.
  • Andrea Sáez was COO/CSO at Origo Biopharma where she led the development of ALK5 inhibitor programs through preclinical and early clinical stages.

AWS Joins Forces With Amgen on Generative AI Solutions to Accelerate Advanced Therapies

Retrieved on: 
Tuesday, November 28, 2023

At AWS re:Invent, Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), today announced that Amgen is expanding its work with AWS to create generative artificial intelligence (generative AI)-based solutions to help discover, develop, and increase the manufacturing throughput of medicines for patients suffering from serious illnesses.

Key Points: 
  • At AWS re:Invent, Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), today announced that Amgen is expanding its work with AWS to create generative artificial intelligence (generative AI)-based solutions to help discover, develop, and increase the manufacturing throughput of medicines for patients suffering from serious illnesses.
  • The platform will help reduce operator intervention and improve ergonomic safety of manual activity by using AI, sensors, and machine vision systems in the packaging lines.
  • “Based on our longstanding AI work, generative AI is helping us improve clinical trial planning, execution, and documentation.
  • “Our life sciences customers are looking to the potential of generative AI to help accelerate innovation and increase efficiencies across the care continuum,” said Dr. Matt Wood, vice president of technology at AWS.

Global CD19 Antibody Market and Clinical Pipeline Outlook 2023-2028: A $10 Billion+ Market by 2028 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 22, 2023

The "Global CD19 Antibody Market and Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global CD19 Antibody Market and Clinical Pipeline Outlook 2028" report has been added to ResearchAndMarkets.com's offering.
  • This can be attributed to the rapid regulatory approvals, and the current pipeline of investigational CD19-targeting therapies shows potential for a further surge of this market cap.
  • CD19-targeting therapies have made a significant impact on the clinical landscape of cancer treatment.
  • Global CD19 Antibody Market and Clinical Pipeline Outlook 2028 Report Highlights:
    Global CD19 Antibody Market Opportunity: > USD 10 Billion By 2028
    Commercially Approved CD 19 Antibodies: 10 Antibodies
    Comprehensive Insights On CD19 Antibodies In Clinical Trials: > 190 Antibodies
    Global CD19 Antibodies Clinical Trials By Company, Indication and Phase

AMGEN ANNOUNCES EXECUTIVE APPOINTMENTS TO ACCELERATE INNOVATION

Retrieved on: 
Thursday, December 14, 2023

THOUSAND OAKS, Calif., Dec. 14, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced two changes to its senior leadership team in the areas of research and development (R&D) and technology, underscoring the advancement of the company's robust pipeline and its commitment to ongoing scientific and technological innovation. James Bradner, M.D., has joined Amgen as executive vice president of Research and Development, and chief scientific officer. Bradner is succeeding David M. Reese, M.D., who has been appointed executive vice president and chief technology officer. Both Bradner and Reese will report to Robert A. Bradway, chairman and chief executive officer at Amgen.

Key Points: 
  • James Bradner, M.D., has joined Amgen as executive vice president of Research and Development, and chief scientific officer.
  • Both Bradner and Reese will report to Robert A. Bradway, chairman and chief executive officer at Amgen.
  • "For more than 40 years, Amgen's focus on innovation has enabled us to deliver life-changing medicines to patients suffering from serious diseases around the world," said Robert A. Bradway, chairman and chief executive officer at Amgen.
  • At Amgen we have been preparing for this moment for over a decade," said David M. Reese, executive vice president and chief technology officer at Amgen.

FDA Grants Priority Review to Amgen's Tarlatamab Application for Advanced Small Cell Lung Cancer

Retrieved on: 
Wednesday, December 13, 2023

THOUSAND OAKS, Calif., Dec. 13, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the Company's Biologics License Application (BLA) for tarlatamab.

Key Points: 
  • Tarlatamab is a potential first-in-class, investigational delta-like ligand 3 (DLL3) targeting Bispecific T-cell Engager (BiTE®) therapy for the treatment of adult patients with advanced small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
  • The FDA grants Priority Review to applications for medicines that offer, if approved, significant improvements over available options or may provide a treatment option where no adequate therapy currently exists.
  • Based on the Priority Review designation, the Prescription Drug User Fee Action (PDUFA) date for tarlatamab is June 12, 2024.
  • The application is being reviewed by the FDA under the Project Orbis framework and Real Time Oncology Review (RTOR).

AMGEN HIGHLIGHTS HEMATOLOGY PORTFOLIO AT ASH 2023

Retrieved on: 
Friday, December 8, 2023

THOUSAND OAKS, Calif., Dec. 8, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data from its blood cancer portfolio and pipeline at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from Dec. 9-12 in San Diego.

Key Points: 
  • THOUSAND OAKS, Calif., Dec. 8, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data from its blood cancer portfolio and pipeline at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from Dec. 9-12 in San Diego.
  • "Data at this year's ASH meeting illustrate the expanding potential of our innovative hematology medicines, BLINCYTO and KYPROLIS, as well as our commitment to providing additional treatment options with our biosimilar eculizumab," said David M. Reese, M.D., executive vice president of Research and Development at Amgen.
  • "As the pioneer of T-cell engager technology and building on nearly a decade of real-world experience, we continue to advance our first-in-class BiTE® molecule, BLINCYTO, into earlier lines of treatment where we have seen encouraging data in patients living with acute lymphoblastic leukemia."
  • Preliminary Results of the Gimema ALLL2820 Trial
    Abstract # 4249 , Session #614, Monday, December 11 from 6:00 - 8:00 p.m. PT
    *E1910 is sponsored by National Cancer Institute (NCI), part of the National Institutes of Health, and conducted by the NCI Funded National Clinical Trial Network.

Red Biotechnology Market to Reach $1,513.22 Billion, Globally, by 2030 at 10.7% CAGR: Coherent Market Insights

Retrieved on: 
Friday, December 8, 2023

Red biotechnology plays a crucial role in the development of innovative treatments and therapies for these diseases.

Key Points: 
  • Red biotechnology plays a crucial role in the development of innovative treatments and therapies for these diseases.
  • This has led to the introduction of innovative products and treatment options in the market, thereby driving the growth of the Red Biotechnology Market .
  • The market for biopharmaceuticals is expected to experience significant growth in the red biotechnology market.
  • The other applications, including animal biotechnology, environmental biotechnology, medical biotechnology, industrial biotechnology, and agricultural biotechnology, also show potential growth.

Chronic Rhinosinusitis with Nasal Polyps Market to Witness Upsurge in Growth at a CAGR of 10.03% During the Study Period (2019-2032), Examines DelveInsight

Retrieved on: 
Thursday, December 7, 2023

LAS VEGAS, Dec. 7, 2023 /PRNewswire/ -- DelveInsight's Chronic Rhinosinusitis with Nasal Polyps Market Insights report includes a comprehensive understanding of current treatment practices, chronic rhinosinusitis with nasal polyps emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • Leading chronic rhinosinusitis with nasal polyps companies such as AstraZeneca, Amgen, GlaxoSmithKline, Keymed Biosciences, Biohaven Pharmaceuticals, and others are developing novel chronic rhinosinusitis with nasal polyps drugs that can be available in the chronic rhinosinusitis with nasal polyps market in the coming years.
  • The promising chronic rhinosinusitis with nasal polyps therapies in the pipeline include FASENRA (benralizumab), TEZSPIRE (tezepelumab), Depemokimab/GSK3511294, CM310, NURTEC (rimegepant), and others.
  • Chronic rhinosinusitis is an inflammatory disease of the paranasal sinuses and nasal tube lining that lasts for more than 4 to 12 weeks.
  • To know more about chronic rhinosinusitis with nasal polyps treatment guidelines, visit @ Chronic Rhinosinusitis with Nasal Polyps Management

Chronic Rhinosinusitis with Nasal Polyps Market to Witness Upsurge in Growth at a CAGR of 10.03% During the Study Period (2019-2032), Examines DelveInsight

Retrieved on: 
Thursday, December 7, 2023

LAS VEGAS, Dec. 7, 2023 /PRNewswire/ -- DelveInsight's Chronic Rhinosinusitis with Nasal Polyps Market Insights report includes a comprehensive understanding of current treatment practices, chronic rhinosinusitis with nasal polyps emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • Leading chronic rhinosinusitis with nasal polyps companies such as AstraZeneca, Amgen, GlaxoSmithKline, Keymed Biosciences, Biohaven Pharmaceuticals, and others are developing novel chronic rhinosinusitis with nasal polyps drugs that can be available in the chronic rhinosinusitis with nasal polyps market in the coming years.
  • The promising chronic rhinosinusitis with nasal polyps therapies in the pipeline include FASENRA (benralizumab), TEZSPIRE (tezepelumab), Depemokimab/GSK3511294, CM310, NURTEC (rimegepant), and others.
  • Chronic rhinosinusitis is an inflammatory disease of the paranasal sinuses and nasal tube lining that lasts for more than 4 to 12 weeks.
  • To know more about chronic rhinosinusitis with nasal polyps treatment guidelines, visit @ Chronic Rhinosinusitis with Nasal Polyps Management